ReviewDiagnostics (Basel, Switzerland)2021
New Predictive Biomarkers for Ovarian Cancer.
Review in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Associated Factors of Ovarian Cancer and Endometrial Cancer in Indonesia. A Study for Developing Artificial-Intelligence-Based Screening Tools
Clinical and Pathological Characteristics of Women With Ovarian Cancers, A National, Retrospective Cross-Sectional Study in Syria During the War
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 105 citations in OpenAlex.
- Prognostic significance of systemic immune-inflammation index in patients with ovarian cancer: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Platelet activation and eicosanoid signaling in ovarian cancer: implications for biomarker development.Molecular biology reports · 2026Review
- Integrated Single-Cell Whole-Genome Sequencing and Spatial Transcriptomics Reveal Intratumoral Heterogeneity in Ovarian Cancer.Cancer research communications · 2026Article
- Global epidemiology of ovarian cancer: patterns, trends, and risk factors.Cancer biology & medicine · 2026Review
- Prognostic and Predictive Significance of Cancer Stem Cell Markers (ZIP-4 and ALDH1A1) in Ovarian Serous Carcinoma Patients: An Immunohistochemical Study.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- A cross-validated deep learning framework for automated detection of DMBA-induced ovarian cancer from histopathological images with CA-125 biomarker support.Frontiers in artificial intelligence · 2026Article
- FOLR1 Regulates the Malignant Progression of Glioblastoma through the SRC/ERK1/2 Axis.Combinatorial chemistry & high throughput screening · 2026Article
- Soft and Strong: Elastic Conductors with Bio-Inspired Self-Protection.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Cancer-associated fibroblasts at the crossroads of tumor progression and therapy resistance: from heterogeneity to precision reprogramming.Journal of the Egyptian National Cancer Institute · 2025Review
- Metabolomics Plasma Biomarkers Associated with the HRD Phenotype in Ovarian Cancer.Metabolites · 2025Article
- Review
- Identification of novel biomarkers for epithelial ovarian cancer through machine learning and explainable artificial intelligence using in silico and in vitro analysis.Scientific reports · 2025Article
- Identification of key candidate genes for ovarian cancer using integrated statistical and machine learning approaches.Briefings in bioinformatics · 2025Article
- Integrated single-cell whole genome sequencing and spatial transcriptomics reveal latent intra-tumoral heterogeneity in ovarian cancer.bioRxiv : the preprint server for biology · 2025Article
- A Review on Biomarker-Enhanced Machine Learning for Early Diagnosis and Outcome Prediction in Ovarian Cancer Management.Cancer medicine · 2025Review
- Plasma Concentrations of Matrilysins (MMP-7, MMP-26) and Stromelysins (MMP-3, MMP-10) as Diagnostic Biomarkers in High-Grade Serous Ovarian Cancer Patients.International journal of molecular sciences · 2025Article
- The Application of Circulating Tumour DNA (ctDNA) in the Diagnosis, Prognosis, and Treatment Monitoring of Gynaecological and Breast Cancers (Review).Diagnostics (Basel, Switzerland) · 2025Review
- Role of Immunotherapy in Ovarian Cancer: Advances, Challenges, and Future Perspectives.Cancer treatment and research · 2025Review
- Value of miR200b and its combination with other biochemical markers in the diagnosis of epithelial ovarian cancer.Molecular biology reports · 2024Article
- The mechanism of sevoflurane affecting ovarian cancer cell proliferation and migration by regulating RNA methylase TRDMT1 to activate the β-catenin pathway.Cell biology and toxicology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is the eighth-most common cause of death among women worldwide. In the absence of distinctive symptoms in the early stages, the majority of women are diagnosed in advanced stages of the disease. Surgical debulking and systemic adjuvant chemotherapy remain the mainstays of treatment, with the development of chemoresistance in up to 75% of patients with subsequent poor treatment response and reduced survival. Therefore, there is a critical need to revisit existing, and identify potential biomarkers that could lead to the development of novel and more effective predictors for ovarian cancer diagnosis and prognosis. The capacity of these biomarkers to predict the existence, stages, and associated therapeutic efficacy of ovarian cancer would enable improvements in the early diagnosis and survival of ovarian cancer patients. This review not only highlights current evidence-based ovarian-cancer-specific prognostic and diagnostic biomarkers but also provides an update on various technologies and methods currently used to identify novel biomarkers of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.